Beth Seidenberg is a partner with Kleiner Perkins Caufield & Byers. She joined the firm in May 2005 to work in the life sciences area.
For the past 20 years, she has focused her career on introducing new innovative treatments for AIDS, arthritis, asthma, cancer, psoriasis, cardiovascular, metabolic, neurological and renal disorders. She introduced 10 innovative products to market and achieved over 40 regulatory approvals (including new indications and formulations) on a worldwide basis. These products have been successfully commercialized and have generated several billion dollars of revenue.
Prior to joining KPCB, Beth was Senior Vice President, Global Development, and Chief Medical Officer at Amgen, Inc., the world’s largest biotechnology company. During Beth’s three years there, her responsibilities included: all stages of clinical research, regulatory affairs, safety, health economics/reimbursement and medical affairs. Prior to joining Amgen, Beth was a senior executive in research and development at Bristol-Myers Squibb Company and Merck & Co., Inc. She began her career in basic and clinical research at the National Institutes of Health specializing in immunology and infectious diseases.
Beth received her BS from Barnard College magna cum laude, Phi Beta Kappa; and her medical degree from the University Of Miami School Of Medicine, alpha omega alpha. Her post-graduate training was completed at Johns Hopkins, George Washington School of Medicine and the National Institutes of Health.
November 19, 2019
© 2007-2019, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.